Circulating cells and exosomes in acute myelogenous leukemia and their role in disease progression and survival

Miyamoto, Kendi Nishino; Bonatto, Diego

doi:10.1016/j.clim.2020.108489

Cited by 5 publications

(2 citation statements)

References 96 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Conversely, the reduced homology between mutations detected on exosomal dsDNA and PB cells may be affected by the study of exosomes instead of EVs at all [ 44 ] or by the detection of EVs released by non-circulating cells [ 45 ]. Exosomes may be released during particular moments of cell life and circulating leukemic cells could be less involved in exosomes release than BM leukemic cells, which are stimulated also by the BM niche [ 46 , 47 ]. So, exosomes may be considered to be effective messengers from the bone marrow.…”

Section: Discussionmentioning

confidence: 99%

Feasibility of Leukemia-Derived Exosome Enrichment and Co-isolated dsDNA Sequencing in Acute Myeloid Leukemia Patients: A Proof of Concept for New Leukemia Biomarkers Detection

Bernardi

Farina

Bosio

et al. 2022

Cancers

View full text Add to dashboard Cite

Exosomes are extracellular vesicles playing a pivotal role in the intercellular communication. They shuttle different cargoes, including nucleic acids from their cell of origin. For this reason, they have been studied as carriers of tumor markers in different liquid biopsy approaches, in particular for solid tumors. Few data are available concerning exosomes as markers of myeloid neoplasia. To better understand their real potential and the best approach to investigate leukemic exosomes, we present the results of a pilot feasibility study evaluating the application of next-generation sequencing analysis of dsDNA derived from exosomes isolated in 14 adult patients affected by acute myeloid leukemias. In particular, leukemia-derived exosome fractions have been analyzed. The concentration of dsDNA co-extracted with exosomes and the number and types of mutations detected were considered and compared with ones identified in the Bone Marrow (BM) and Peripheral Blood (PB) cells. Exosomal DNA concentration, both considering the cargo and the DNA surrounding the lipid membrane resulted in a linear correlation with leukemic burden. Moreover, exosomal DNA mutation status presented 86.5% of homology with BM and 75% with PB. The results of this pilot study confirmed the feasibility of a leukemia-derived exosome enrichment approach followed by exosomal dsDNA NGS analysis for AML biomarker detection. These data point to the use of liquid biopsy in myeloid neoplasia for the detection of active leukemic cells resident in the BM via a painless procedure.

show abstract

Section: Discussionmentioning

confidence: 99%

Feasibility of Leukemia-Derived Exosome Enrichment and Co-isolated dsDNA Sequencing in Acute Myeloid Leukemia Patients: A Proof of Concept for New Leukemia Biomarkers Detection

Bernardi

Farina

Bosio

et al. 2022

Cancers

View full text Add to dashboard Cite

show abstract

“…AML can reconstitute the BM microenvironment to one that promotes the growth of leukemic cells but inhibits normal hematopoietic function by secreting exosomes. Exosomes released by AML cells upregulate DKK1 in BM mesenchymal stromal cells and thereby inhibit normal hematopoiesis through the WNT signaling pathway, and AML-derived exosomes stimulate vascular endothelial growth factor (VEGF) signaling in human umbilical vein endothelial cells (HUVECs) by transferring angiogenic factors or proteins and miRNAs, which form vascular tubular structures that promote tumor growth ( 4 , 67 ). Some studies have confirmed that exosomal miRNAs secreted by AML cells contribute to the progression of AML by altering the expression of downstream genes ( 68 ).…”

Section: Aml-derived Exosomes Related To Aml Progressmentioning

confidence: 99%

Utilizing exosomes as sparking clinical biomarkers and therapeutic response in acute myeloid leukemia

Wang,

Wu,

Zheng

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

Acute myeloid leukemia (AML) is a malignant clonal tumor originating from immature myeloid hematopoietic cells in the bone marrow with rapid progression and poor prognosis. Therefore, an in-depth exploration of the pathogenesis of AML can provide new ideas for the treatment of AML. In recent years, it has been found that exosomes play an important role in the pathogenesis of AML. Exosomes are membrane-bound extracellular vesicles (EVs) that transfer signaling molecules and have attracted a large amount of attention, which are key mediators of intercellular communication. Extracellular vesicles not only affect AML cells and normal hematopoietic cells but also have an impact on the bone marrow microenvironment and immune escape, thereby promoting the progression of AML and leading to refractory relapse. It is worth noting that exosomes and the various molecules they contain are expected to become the new markers for disease monitoring and prognosis of AML, and may also function as drug carriers and vaccines to enhance the treatment of leukemia. In this review, we mainly summarize to reveal the role of exosomes in AML pathogenesis, which helps us elucidate the application of exosomes in AML diagnosis and treatment.

show abstract

Acute myelogenous leukemia detection using optimal neural network based on fractional black-widow model

Ramya

Lakshmi

2021

SIViP

View full text Add to dashboard Cite

Circulating cells and exosomes in acute myelogenous leukemia and their role in disease progression and survival

Cited by 5 publications

References 96 publications

Feasibility of Leukemia-Derived Exosome Enrichment and Co-isolated dsDNA Sequencing in Acute Myeloid Leukemia Patients: A Proof of Concept for New Leukemia Biomarkers Detection

Feasibility of Leukemia-Derived Exosome Enrichment and Co-isolated dsDNA Sequencing in Acute Myeloid Leukemia Patients: A Proof of Concept for New Leukemia Biomarkers Detection

Utilizing exosomes as sparking clinical biomarkers and therapeutic response in acute myeloid leukemia

Acute myelogenous leukemia detection using optimal neural network based on fractional black-widow model

Contact Info

Product

Resources

About